Lyotropic liquid crystalline self-assembly material behavior and nanoparticulate dispersions of a phytanyl pro-drug analogue of capecitabine-a chemotherapy agent

ACS Appl Mater Interfaces. 2011 May;3(5):1552-61. doi: 10.1021/am200117u. Epub 2011 Apr 12.

Abstract

An amphiphile prodrug, 5'-deoxy-5-fluoro-N⁴-(phytanyloxycarbonyl) cytidine (5-FCPhy) has been prepared and investigated for its self-assembly material properties, in vitro cytotoxicity, and in vivo efficacy as a chemotherapy agent. The phase transitions and stability of the neat amphiphile were characterized by differential scanning calorimetry (DSC) and thermogravimetric analysis (TGA). X-ray diffraction (XRD) was used to confirm the structure of the neat amphiphile, which was an amorphous glassy material. The lyotropic liquid crystalline self-assembly behavior of the amphiphile prodrug in water was examined by cross polarizing optical microscopy (POM) and small-angle X-ray scattering (SAXS). Under excess water conditions at room temperature, the amphiphile prodrug self-assembles into lyotropic liquid crystalline mesophases of inverse bicontinuous cubic symmetry. Upon aging, the inverse cubic phase slowly transformed to an inverse hexagonal phase. This amphiphile was successfully dispersed into nanoparticles of cubic and hexagonal symmetry. The in vitro cytotoxicity of dispersed nanoparticles was evaluated in seven different normal and cancer cell types and exhibited IC₅₀ values between 70 and 90 μM for all cell types. Evaluation of 5-FCPhy in vivo against a mouse 4T1 breast tumor model displayed a trend of increasing efficacy with increasing dose. Furthermore, after 21 days, tumor volumes in the 0.5 mmol 5-FCPhy treatment group were significantly smaller than all other treatment groups including mice receiving a short chain water-soluble analogue, Capecitabine (a commercially available oral chemotherapy agent), delivered at the same dosage.

MeSH terms

  • Animals
  • Antineoplastic Agents / administration & dosage*
  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / chemistry
  • Antineoplastic Agents / metabolism*
  • Breast Neoplasms / drug therapy
  • Capecitabine
  • Cell Survival
  • Deoxycytidine / administration & dosage
  • Deoxycytidine / adverse effects
  • Deoxycytidine / analogs & derivatives*
  • Deoxycytidine / chemistry
  • Deoxycytidine / metabolism
  • Drug Stability
  • Female
  • Fluorouracil / administration & dosage
  • Fluorouracil / adverse effects
  • Fluorouracil / analogs & derivatives*
  • Fluorouracil / chemistry
  • Fluorouracil / metabolism
  • Inhibitory Concentration 50
  • Liquid Crystals / chemistry*
  • Mice
  • Phase Transition
  • Prodrugs / administration & dosage*
  • Prodrugs / adverse effects
  • Prodrugs / chemistry
  • Prodrugs / metabolism*
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • Prodrugs
  • Deoxycytidine
  • Capecitabine
  • Fluorouracil